|
Market Closed -
Euronext Paris
12:55:00 2026-10-28 EDT
|
Pre-market 02:05:02 | |||
| 347.50 EUR | -0.29% |
|
347.75 | +0.07% |
| 10-20 | Virbac: A well-done Q3 validates underlying quality |  |
| 10-20 | Virbac stock little changed despite strong update and targets now expected at the top end of the range |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Veterinary Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.25B | |||||
| 1,148B | |||||
| 652B | |||||
| 505B | |||||
| 384B | |||||
| 348B |
- Stock Market
- Stocks
- VIRP Stock
- Charts Virbac
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
